With Heterocyclic Compound Patents (Class 514/161)
-
Patent number: 8883767Abstract: A low ether gel composition for application to skin comprising a keratolytic agent, in particular salicylic acid, and comprising a nitrocellulose and one or more volatile ingredients, which forms a film on contact with skin adequate to form a protective barrier for the keratolytic agent for a period of time necessary to provide treatment to the skin; methods of treating using such compositions, and dispensers containing such compositions.Type: GrantFiled: October 4, 2010Date of Patent: November 11, 2014Assignee: MSD Consumer Care, Inc.Inventors: Gerald R. Dever, Eric Chen-nan Su, William Scott Rogersr, Robert C. Johnson
-
Publication number: 20140329781Abstract: The present invention relates to a once-a-day therapeutically synergistic pharmaceutical dosage form for treatment of cardiovascular disorders, wherein the dosage form comprises a fixed dose combination of metoprolol in extended release form and one or more antiplatelet agent along with one or more rate controlling excipients.Type: ApplicationFiled: November 1, 2012Publication date: November 6, 2014Applicant: WOCKHARDT LIMITEDInventors: Mandar Kodgule, Amit Gupta, Premchand Nakhat, Girish Kumar Jain
-
Publication number: 20140328775Abstract: A cosmetic composition suitable for topical application, for example, is provided. In some examples, the cosmetic composition may include batyl alcohol, undecylenoyl phenylalanine, hexyldecanol, and bisabolol. A method of reducing the synthesis of melanin by using the cosmetic compositions is also disclosed herein.Type: ApplicationFiled: May 1, 2014Publication date: November 6, 2014Applicant: The Procter & Gamble CompanyInventors: Leo Timothy LAUGHLIN, II, Tomohiro HAKOZAKI, Shuhei TANAKA
-
Publication number: 20140303074Abstract: The present disclosure provides methods of reducing immunodeficiency virus transcription, involving use of diflunisal or an active ester thereof. The disclosure also provides methods of treating an immunodeficiency virus infection in an individual, the method generally involving administering to the individual an effective amount of diflunisal or an active ester thereof.Type: ApplicationFiled: December 12, 2012Publication date: October 9, 2014Inventors: Eric M. Verdin, Kotaro Shirakawa
-
Publication number: 20140288028Abstract: The present invention provides for salts comprising a compound of Formula I and an acid that has activity against mammalian factor Xa. The present invention is also directed to methods of making the compound of Formula I.Type: ApplicationFiled: February 17, 2014Publication date: September 25, 2014Inventors: Craig Grant, James P. Kanter, Graeme Langlands
-
Publication number: 20140271921Abstract: A topical composition comprises at least 5 wt % metronidazole or a pharmacologically acceptable derivative thereof in a non-aqueous vehicle. The composition may be used in the treatment of conditions of the colon, rectum, anorectum and perianal region, in particular inflammatory bowel disease and perianal Crohn's disease. The composition also relieves pain and inflammation and promotes healing of the colon, rectum, anorectum and perianal region following surgical operations. One advantage of the composition is that topical administration of metronidazole results in a primarily local effect and thus side effects observed from systemic administration are avoided.Type: ApplicationFiled: May 28, 2014Publication date: September 18, 2014Applicant: SLA PHARMA AGInventor: DAVID NIGEL ARMSTRONG
-
Patent number: 8828978Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.Type: GrantFiled: May 7, 2013Date of Patent: September 9, 2014Assignee: KemPharm, Inc.Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
-
Publication number: 20140234420Abstract: The present invention describes methods and compositions for treating diverse dermatological conditions, including acne and psoriasis, using zein containing nanocarrier devices for topical delivery of methotrexate, retinoic acid and benzoyl peroxide to select targets in the skin.Type: ApplicationFiled: August 14, 2013Publication date: August 21, 2014Inventors: Omathanu P. Perumal, Ranjith Kumar Averineni
-
Publication number: 20140227356Abstract: The present invention relates to a hard capsule composite formulation comprising a capsule having a hemispherical closure at each end and an interior space; and one or more tablets encapsulated in the capsule, wherein the tablet or the tablets as a whole have a shape conforming to the internal space of the capsule. The hard capsule composite formulation can efficiently charge pharmaceutical compositions inside the limited interior space of the capsule, and hence, it allows packing a high-dose of pharmaceutical composition in a relatively small-sized capsule, which increases productivity and patient compliance. Also, the composite formulation exhibits good dissolution rate because pharmaceutically active ingredients contained in the capsule are separated from one another, and thus, the ingredients are less affected by the dissolution rate of one another, allowing good storage stability which can optimize the therapeutic effects.Type: ApplicationFiled: October 15, 2012Publication date: August 14, 2014Applicant: HANMI PHARM CO., LTD.Inventors: Kyeong Soo Kim, Ki Young Jang, Seung Jae Park, Yong Il Kim, Jae Hyun Park, Jong Soo Woo
-
Publication number: 20140221906Abstract: The present system and method relates in general to treating warts using a triple combination of therapies contained within a kit. The therapies are easy for a patient to self-apply, eliminating the need for constant physician supervision. The first therapy involves a patient applying a patch within the kit to a wart, which may be in the form of a transdermal patch. The patch may contain a first medicine, such as salicylic acid, and be worn for a period of twelve hours. Once removed, the second therapy involves using an ablative tool to gently slough away the treated wart, said ablative tool being contained within the kit. The third therapy involves applying a second patch, which may contain a second medicine, such as imiquimod, and also be worn for a period of twelve hours. This three step process may be repeated until the wart is fully treated.Type: ApplicationFiled: June 10, 2013Publication date: August 7, 2014Inventor: Jake W. Townsend
-
Publication number: 20140220124Abstract: A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component.Type: ApplicationFiled: January 10, 2014Publication date: August 7, 2014Applicant: Vitalis LLCInventor: Joseph Peter Habboushe
-
Publication number: 20140221322Abstract: Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).Type: ApplicationFiled: November 5, 2013Publication date: August 7, 2014Applicant: JANSSEN PHARMACEUTICA NVInventors: J. Guy Breitenbucher, John M. Keith, Mark S. Tichenor, Alison L. Chambers, William M. Jones, Natalie A. Hawryluk, Amy K. Timmons, Jeffrey E. Merit, Mark J. Selerstad
-
Publication number: 20140193346Abstract: Herbal composition and method for the treatment of inflammatory pain associated with tendonitis, bursitis, arthritis, carpal tunnel syndrome, tennis elbow, plantar fasciitis, sports injuries, lower back pain and overexertion, gingivitis and muscle aches, that is compliant with HPUS monographs and/or over-the-counter FDA topical analgesic monograph requirements.Type: ApplicationFiled: January 7, 2013Publication date: July 10, 2014Applicant: DRT LABORATORIES LLCInventor: Ronit Arginteanu
-
Publication number: 20140187517Abstract: The present disclosure relates to methods for treating intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease or diverticular disease and/or maintaining remission of intestinal diseases presenting at least one inflammatory component such as inflammatory bowel disease (IBD) or diverticular disease using budesonide MMX compositions.Type: ApplicationFiled: March 5, 2014Publication date: July 3, 2014Applicants: SANTARUS, INC., COSMO TECHNOLOGIES LIMITEDInventors: Gerald Thomas PROEHL, Wendell WIERENGA, Michael Fangching HUANG, Emerson David BALLARD, II, Luigi MORO
-
Patent number: 8765723Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.Type: GrantFiled: January 7, 2013Date of Patent: July 1, 2014Assignee: CoNCERT Pharmaceuticals, Inc.Inventors: Rose A. Persichetti, Julie F. Liu, Craig E. Masse, Scott L. Harbeson
-
Publication number: 20140179642Abstract: Methods for preventing, ameliorating, or reducing dermatological signs of aging are provided which employ cosmetic composition comprising novel active agents that enhance collagen production in the skin.Type: ApplicationFiled: December 20, 2012Publication date: June 26, 2014Applicant: AVON PRODUCTS, INC.Inventors: Uma Santhanam, Permanan Raaj Khusial
-
Publication number: 20140178441Abstract: Methods and compositions for reducing frequency of urination are disclosed. One method comprises administering to a subject in need thereof an effective amount of a pharmaceutical composition comprising one or more analgesic agents.Type: ApplicationFiled: March 4, 2014Publication date: June 26, 2014Applicant: WELLESLEY PHARMACEUTICALS, LLCInventor: David A. DILL
-
Patent number: 8759326Abstract: Drug combinations which contain a PDE4-inhibitor and a non-steroidal anti-inflammatory drug (NSAID), processes for preparing them, and their use in treating in particular respiratory complaints such as COPD, chronic sinusitis, and asthma. The PDE4 inhibitors of the drug combinations include compounds of general formula 1 wherein X is SO or SO2, but preferably SO, R3 is an optionally substituted, mono- or bicyclic, unsaturated, partly saturated or saturated heterocyclic group or an optionally substituted, mono- or bicyclic heteroaryl, and R1 and R2 have the meanings given in claim 1.Type: GrantFiled: August 15, 2013Date of Patent: June 24, 2014Assignee: Boehringer Ingelheim International GmbHInventors: Peter Nickolaus, Rolf Goeggel, Daniel Peter
-
Patent number: 8759325Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: February 21, 2012Date of Patent: June 24, 2014Assignee: The Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20140170112Abstract: In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising a combination regimen of at least two active ingredients designed to diminish systemic inflammation by targeting (inhibiting) two different, but convergent, signaling pathways, i.e., the sympathetic nervous system and the lipid-derived autacoid system; and methods for making and using these compositions. In alternative embodiments, the compositions of the invention (e.g., the combination of drugs) are used to ameliorate, diminish, treat, block or prevent an inflammatory response secondary to an infection, e.g., a viral infection and/or a reactivation.Type: ApplicationFiled: March 8, 2012Publication date: June 19, 2014Applicant: VICUS THERAPEUTICS, LLCInventors: John Maki, Newell Bascomb, Timothy J. Turner, Fredric Young
-
Publication number: 20140162987Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a severe pain in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: June 12, 2014Applicant: BIOCOPEA LIMITEDInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Publication number: 20140162874Abstract: This document discloses molecules having the following formula (“Formula One”): and processes related thereto.Type: ApplicationFiled: February 12, 2014Publication date: June 12, 2014Applicant: DOW AGROSCIENCES LLCInventors: Maurice C. Yap, Ann M. Buysse, Daniel Knueppel, Yu Zhang, Negar Garizi, Noormohamed M. Niyaz, Christian T. Lowe, Ricky Hunter, Tony K. Trullinger, David A. Demeter, Dan Pernich, Carl DeAmicis, Ronald Ross, JR., Timothy C. Johnson
-
Patent number: 8748413Abstract: The presently described technology provides compositions comprising aryl carboxylic acids chemically conjugated to hydrocodone (morphinan-6-one, 4,5-alpha-epoxy-3-methoxy-17-methyl) to form novel prodrugs/compositions of hydrocodone, including benzoates and heteroaryl carboxylic acids, which have a decreased potential for abuse of hydrocodone. The present technology also provides methods of treating patients, pharmaceutical kits and methods of synthesizing conjugates of the present technology.Type: GrantFiled: May 7, 2013Date of Patent: June 10, 2014Assignee: KemPharm, Inc.Inventors: Travis Mickle, Sven Guenther, Christal Mickle, Guochen Chi, Jaroslaw Kanski, Andrea K. Martin, Bindu Bera
-
Publication number: 20140154189Abstract: The present invention, therefore, is directed to an antimicrobial compositions that decreases the bioavailability of iron by introducing a higher-affinity iron-selective chelating agent capable of competing with microbial siderophores. In one aspect, the present invention relates to an antimicrobial composition including a potentiating antimicrobial composition including one or more antimicrobial agents and a chelator having a weight ratio of the antimicrobial agent to the chelator from about 1:1000 to about 1000:1.Type: ApplicationFiled: October 14, 2013Publication date: June 5, 2014Applicant: Arch Chemicals, Inc.Inventors: George Polson, Jody Jourden, Qi Zheng, Regina M. Prioli, Diana Ciccognani, Sungmee Choi
-
Publication number: 20140147505Abstract: The present invention relates to a solid pharmaceutical dosage form comprising ticagrelor as pharmaceutically active ingredient, to certain particles of ticagrelor and to processes of preparing the same.Type: ApplicationFiled: January 29, 2014Publication date: May 29, 2014Applicant: ratiopharm GmbHInventors: Sandra BRUECK, Dominique MEERGANS
-
Publication number: 20140147448Abstract: The invention includes compositions and methods useful for treating preventing abnormal thrombus formation and subsequent cardiovascular disease in diabetic patients and patients with increased cardiovascular risk.Type: ApplicationFiled: June 5, 2012Publication date: May 29, 2014Applicant: Yale UniversityInventors: John Hwa, WaiHo Tang
-
Publication number: 20140134271Abstract: Pyrimidine compounds and their use in controlling pests such as insects and other invertebrates are provided. Further embodiments, forms, objects, features, advantages, aspects and benefits shall become apparent from the description.Type: ApplicationFiled: October 25, 2013Publication date: May 15, 2014Applicant: Dow AgroSciences LLCInventors: Tony K. Trullinger, Timothy C. Johnson, Ricky Hunter
-
Publication number: 20140128353Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: Biocopea LimitedInventors: Robin M. Bannister, John Brew, Richard R. Reiley, III, Wilson Caparros Wanderley
-
Patent number: 8715721Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.Type: GrantFiled: May 23, 2013Date of Patent: May 6, 2014Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Hua-Pin Huang, John K. Masselink, Alfred Tonelli
-
Publication number: 20140107040Abstract: Disclosed herein are substituted N-Aryl pyridinone fibrotic inhibitors and/or collagen infiltration modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.Type: ApplicationFiled: December 18, 2013Publication date: April 17, 2014Applicant: Auspex Pharmaceuticals, Inc.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Publication number: 20140094438Abstract: The claimed invention relates to compositions that may be in a form of a liquid, solid, gel, cream or gel capsule comprising an analgesic, and methods for administering these compositions for treatment of patients suffering from various forms of pain.Type: ApplicationFiled: October 1, 2013Publication date: April 3, 2014Applicant: GM Pharmaceuticals, Inc.Inventor: Odes W. Mitchell
-
Publication number: 20140079685Abstract: A method and composition for treating serotonin receptor-mediated conditions.Type: ApplicationFiled: November 25, 2013Publication date: March 20, 2014Applicant: Vanda Pharmaceuticals Inc.Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt Wolfgang
-
Publication number: 20140066412Abstract: Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).Type: ApplicationFiled: November 6, 2013Publication date: March 6, 2014Inventors: J. Guy Breitenbucher, John M. Keith, Mark S. Tichenor, Alison L. Chambers, William M. Jones, Natalie A. Hawryluk, Amy K. Timmons, Jeffrey E. Merit, Mark J. Selerstad
-
Publication number: 20140066413Abstract: A soluble aspirin composition, comprising: (i) granules including aspirin, heat-treated bicarbonate salt, pharmaceutically-acceptable resin and surfactant, in mixture with: (ii) crystalline particles of pharmaceutically-acceptable acid; and (iii) crystalline particles of heat-treated bicarbonate salt; wherein the soluble aspirin composition when introduced to water undergoes reaction of the crystalline particles of pharmaceutically-acceptable acid with the heat-treated bicarbonate salt and the aspirin to effect effervescing action and disintegration of the granules with conversion of the aspirin to an acetylsalicylate compound of the bicarbonate salt cation so that the composition rapidly dissolves in the water without occurrence of undissolved residue. The composition is solubilizable within 30 seconds in cool to cold water to provide an effervescent analgesic solution that can be readily orally administered to an individual in need of analgesia.Type: ApplicationFiled: November 11, 2013Publication date: March 6, 2014Applicant: Aspir-Tek, Inc.Inventor: Howard Phykitt
-
Publication number: 20140057883Abstract: This application provides for a method of treating a subject suffering from Crohn's disease, the method comprising periodically administering to the subject an amount of laquinimod or pharmaceutically acceptable salt thereof effective to treat the subject. This application provides for use of laquinimod in the manufacture of a medicament for treating a subject suffering from Crohn's disease. This application also provides for a pharmaceutical composition comprising laquinimod for use in treating a subject suffering from Crohn's disease.Type: ApplicationFiled: October 29, 2013Publication date: February 27, 2014Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Nora Tarcic, Asi Haviv, Eran Blaugrund, Joel Kaye
-
Patent number: 8658620Abstract: One embodiment of the present invention is a pharmaceutical composition comprising at least one specific 2-iminopyrrolidine derivative and at least one other compound (B). Another embodiment of the present invention is a pharmaceutical composition comprising at least one specific 2-iminopyrrolidine derivative, which is to be used in combination with at least one other compound (B). According to the present invention, there are provided pharmaceutical compositions capable of treating or ameliorating diseases, such as heart diseases, effectively.Type: GrantFiled: January 9, 2009Date of Patent: February 25, 2014Assignee: Eisai R&D Management Co., Ltd.Inventor: Motoji Kogushi
-
Publication number: 20140050714Abstract: The present invention concerns a method for modulating the enzymatic activity of an enzyme, wherein said enzyme interacts with BMP, said method comprising the step of administering or inducing Hsp70, or a functional fragment or variant thereof, in a form suitable for allowing interaction between BMP and Hsp70, or said functional fragment or variant thereof, and thereby modulating the enzymatic activity of an enzyme interacting with BMP.Type: ApplicationFiled: August 19, 2013Publication date: February 20, 2014Applicant: ORPHAZYME APSInventors: Thomas Kirkegaard Jensen, Marja H. Jaattela
-
Publication number: 20140045800Abstract: Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).Type: ApplicationFiled: February 4, 2013Publication date: February 13, 2014Applicant: The Scripps Research InstituteInventor: Dale L. Boger
-
Patent number: 8647667Abstract: A solid oral controlled-release dosage form of hydrocodone is disclosed, the dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and controlled release material.Type: GrantFiled: May 24, 2013Date of Patent: February 11, 2014Assignee: Purdue Pharma, L.P.Inventors: Benjamin Oshlack, Hua-Pin Huang, John K. Masselink, Alfred P. Tonelli
-
Publication number: 20140038924Abstract: New compounds, namely, (7aS,2?S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.Type: ApplicationFiled: October 3, 2013Publication date: February 6, 2014Applicant: IPCA LABORATORIES LIMITEDInventors: Ashok Kumar, Satish Rajanikant Soudagar, Nellithanath Thankachen Byju, Gaurav Sahal, Arpana Prashant Mathur, Sanjay Pandurang Gawade, Dinesh Kanji Bhadra, Devki MOJE
-
Publication number: 20140031320Abstract: New compounds, namely, (7aS,2?S)-2-oxoclopidogrel and its pharmaceutically acceptable salts thereof are disclosed for treatment or prophylaxis of thrombo-embolism and/or cardiovascular diseases.Type: ApplicationFiled: October 3, 2013Publication date: January 30, 2014Applicant: IPCA LABORATORIES LIMITEDInventors: Ashok Kumar, Satish Rajanikant Soudagar, Nellithanath Thankachen Byju, Gaurav Sahal, Arpana Prashant Mathur, Sanjay Pandurang Gawade, Dinesh Kanji Bhadra, Devki MOJE
-
Publication number: 20140017226Abstract: This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject fampridine as an add-on therapy to or in combination with laquinimod. This invention also provides a package comprising laquinimod and fampridine for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides fampridine for use as an add-on therapy or in combination with laquinimod in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and fampridine for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.Type: ApplicationFiled: July 11, 2013Publication date: January 16, 2014Applicant: TEVA PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Joel Kaye, Nora Tarcic
-
Patent number: 8629127Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: November 28, 2012Date of Patent: January 14, 2014Assignee: The Regents of the University of OklahomaInventor: Richard F. Harty
-
Patent number: 8623847Abstract: Inflammatory bowel diseases are represented by two idiopathic disorders, which include ulcerative colitis and Crohn's disease. Ulcerative colitis is restricted to the colon and involves uncertain and inflammation of the lining (mucosa) of the large intestine. Crohn's disease, on the other hand, can involve the mucosa of the small and/or large intestine and may involve deeper layers of the bowel wall. The present invention is a combination of 5-aminosalicylic acid and one or more antioxidants (e.g., N-acetylcysteine) for treating such inflammatory bowel diseases.Type: GrantFiled: May 3, 2012Date of Patent: January 7, 2014Assignee: The Regents of the University of OklahomaInventor: Richard F. Harty
-
Publication number: 20140004174Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of histone deacetylase 8 (HDAC8). Also described herein are methods of using such HDAC8 inhibitors, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of HDAC8 activity.Type: ApplicationFiled: May 20, 2013Publication date: January 2, 2014Applicant: Pharmacyclics, Inc.Inventors: Erik VERNER, Sriram BALASUBRAMANIAN, Joseph J. BUGGY
-
Publication number: 20130344184Abstract: The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. The subject invention also concerns compositions formulated for oral administration. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient. In another embodiment, compounds or compositions are orally administered.Type: ApplicationFiled: June 28, 2013Publication date: December 26, 2013Applicant: THERAPEUTIC RESEARCH LLCInventor: Jay PRAVDA
-
Publication number: 20130345182Abstract: The present invention relates to a stable composition for providing substances with different types of activity, such as cholesterol lowering agents, antihypertensive agents and antiplatelet agents, which substantially reduce the dosage required to prevent cardiovascular events.Type: ApplicationFiled: December 21, 2010Publication date: December 26, 2013Inventors: Paola Yazmin Ollervides Rubio, Casimiro Frausto Campos, Antonio Santiago Regalado
-
Publication number: 20130338121Abstract: The present document describes a monolithic tablet dosage form for delivery of an active ingredient at two different release rates comprising a carboxyl polymer complexed with a multivalent cation and a disintegrating agent for a first initial fast release of the active ingredient, and a modulating agent for a second sustained release of the active ingredient. Also described are processes for preparing the carboxyl polymer complexed with a multivalent cation, and carboxyl polymer made from the process.Type: ApplicationFiled: February 28, 2012Publication date: December 19, 2013Inventors: Le Tien Canh, Mircea-Alexandru Mateescu
-
Publication number: 20130316024Abstract: A cosmetic kit and the use thereof for improving the appearance of the skin is described. Further described, is the prevention and/or controlling of cellulite or the orange peel syndrome and/or for slimming down the figure, through the increase of the elasticity and firmness of the skin by stepping up collagen synthesis, for increasing blood microcirculation and for improving thermoregulation of the skin.Type: ApplicationFiled: November 18, 2011Publication date: November 28, 2013Applicant: RHODIA POLIAMIDA E ESPECIALIDADES LTDAInventors: Gabriel Gorescu, Thomas Canova, Tarcis Cordeiro Bastos, Karla Laguens
-
Publication number: 20130315998Abstract: A topical foam pharmaceutical composition for rectal administration comprising rifaximin is described. Also described is a method of making the composition and the use of the composition as a medicament.Type: ApplicationFiled: August 5, 2013Publication date: November 28, 2013Applicant: CIPLA LimitedInventors: Amar Lulla, Geena Malhotra